Trial Profile
A Phase IIIB, Multicentre, Multinational, Randomized, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f Day 1 to Day 5 Followed by Pergoveris Starting Day 6 to Pergoveris Starting Day 1 in Women Between 36 and 40 Years of Age Undergoing Assisted Reproductive Technique (ART)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Follitropin alfa (Primary) ; Follitropin alfa/lutropin alfa (Primary)
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms PERSIST
- Sponsors Merck KGaA; Merck Serono
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Jan 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 24 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.